-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A team led by the Autònoma de Barcelona (INc-UAB) Neurociències Institute at the University of Barcelona has succeeded in reducing chronic inflammation associated with multiple sclerosis in mice by administering a lipid that mediates inflammation
Acute inflammation is a protective response to infection that promotes tissue regeneration after injury
A team led by Rubén López-Vales, professor of physiology at UAB and a researcher in the Neuroplasticity and Regeneration Group INC-UAB, succeeded in reducing the risk of multiple sclerosis by injecting mice with Maresin-1, a lipid-breaking mediator of inflammation.
In the study, published in the Journal of Neuroinflammation, the researchers looked at samples from multiple sclerosis patients and mouse models and found insufficient production of Maresin-1 and other lipid mediators that stop inflammation
"Our findings suggest that one of the mechanisms in people with multiple sclerosis that resolves inflammation is not working properly, which may partly explain the autoimmune events they experience," said Dr.
It points out that treatment with inflammatory breakdown mediators is an innovative and promising strategy for the treatment of multiple sclerosis and other autoimmune diseases, and further research is needed
In the end, López Vales explained that the next steps will be a series of tests and experiments to demonstrate the safety of taking the lipid, which will allow them to address possible efficacy studies in humans
Courtesy of the Autonomous University of Barcelona
